Goldman Sachs’s Albireo Pharma Inc ALBO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-12,706
| Closed | -$275K | – | 6430 |
|
|
2022
Q4 | $275K | Sell |
12,706
-16,869
| -57% | -$357K | ﹤0.01% | 5181 |
|
|
2022
Q3 | $573K | Sell |
29,575
-47,114
| -61% | -$974K | ﹤0.01% | 4888 |
|
|
2022
Q2 | $0 | Buy |
76,689
+33,362
| +77% | +$880K | ﹤0.01% | 6864 |
|
|
2022
Q1 | $1.29M | Sell |
43,327
-128,140
| -75% | -$3.75M | ﹤0.01% | 4617 |
|
|
2021
Q4 | $3.99M | Buy |
171,467
+15,950
| +10% | +$424K | ﹤0.01% | 3633 |
|
|
2021
Q3 | $4.85M | Buy |
155,517
+23,009
| +17% | +$712K | ﹤0.01% | 3392 |
|
|
2021
Q2 | $4.66M | Sell |
132,508
-92,038
| -41% | -$2.99M | ﹤0.01% | 3402 |
|
|
2021
Q1 | $7.92M | Buy |
224,546
+6,409
| +3% | +$237K | ﹤0.01% | 2760 |
|
|
2020
Q4 | $8.18M | Buy |
218,137
+173,977
| +394% | +$6.33M | ﹤0.01% | 2625 |
|
|
2020
Q3 | $1.47M | Buy |
44,160
+25,407
| +135% | +$740K | ﹤0.01% | 3800 |
|
|
2020
Q2 | $497K | Buy |
18,753
+5,413
| +41% | +$128K | ﹤0.01% | 4381 |
|
|
2020
Q1 | $218K | Buy |
13,340
+3,272
| +32% | +$71.9K | ﹤0.01% | 4667 |
|
|
2019
Q4 | $256K | Sell |
10,068
-19,993
| -67% | -$400K | ﹤0.01% | 4808 |
|
|
2019
Q3 | $601K | Buy |
+30,061
| New | +$778K | ﹤0.01% | 4356 |
|
|
2018
Q3 | – | Sell |
-6,025
| Closed | -$214K | – | 5858 |
|
|
2018
Q2 | $214K | Sell |
6,025
-46,082
| -88% | -$1.49M | ﹤0.01% | 4965 |
|
|
2018
Q1 | $1.7M | Buy |
+52,107
| New | +$1.75M | ﹤0.01% | 3712 |
|
|
2016
Q4 | – | Sell |
-564
| Closed | -$7K | – | 7154 |
|
|
2016
Q3 | $7K | Sell |
564
-3
| -0.5% | -$35 | ﹤0.01% | 6907 |
|
|
2016
Q2 | $5K | Sell |
567
-137
| -19% | -$1.51K | ﹤0.01% | 6929 |
|
|
2016
Q1 | $7K | Sell |
704
-104
| -13% | -$925 | ﹤0.01% | 6951 |
|
|
2015
Q4 | $8K | Sell |
808
-9,592
| -92% | -$99.2K | ﹤0.01% | 7005 |
|
|
2015
Q3 | $137K | Sell |
10,400
-17
| -0.2% | -$428 | ﹤0.01% | 6272 |
|
|
2015
Q2 | $322K | Buy |
10,417
+5,852
| +128% | +$197K | ﹤0.01% | 5664 |
|
|
2015
Q1 | $163K | Sell |
4,565
-2,869
| -39% | -$121K | ﹤0.01% | 6149 |
|
|
2014
Q4 | $297K | Buy |
7,434
+1
| +0% | +$44 | ﹤0.01% | 5790 |
|
|
2014
Q3 | $372K | Sell |
7,433
-71
| -0.9% | -$4.08K | ﹤0.01% | 5554 |
|
|
2014
Q2 | $486K | Buy |
7,504
+3,647
| +95% | +$254K | ﹤0.01% | 5348 |
|
|
2014
Q1 | $316K | Buy |
3,857
+70
| +2% | +$6.37K | ﹤0.01% | 5701 |
|
|
2013
Q4 | $259K | Sell |
3,787
-9,091
| -71% | -$666K | ﹤0.01% | 5797 |
|
|
2013
Q3 | $1.22M | Sell |
12,878
-3,331
| -21% | -$434K | ﹤0.01% | 4423 |
|
|
2013
Q2 | $2.03M | Buy |
+16,209
| New | +$1.69M | ﹤0.01% | 3716 |
|
Other funds holding ALBO
Goldman Sachs's ALBO Position: Q1 2023 in Review
Goldman Sachs sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 12,706 shares — an estimated $275K sold.
Goldman Sachs first reported a position in ALBO in Q2 2013 and held it in 30 quarters. The position peaked at $8.18M in Q4 2020. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.
- Goldman Sachs reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
- Goldman Sachs sold 12,706 Albireo Pharma Inc shares in Q1 2023, an estimated $275K.
- Goldman Sachs first reported a position in Albireo Pharma Inc in Q2 2013 and held it in 30 quarters.
- Goldman Sachs's Albireo Pharma Inc position peaked at $8.18M in Q4 2020.
- 3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.
Based on Goldman Sachs's 13F filing for Q1 2023, filed 11 May 2023.